Provided by Tiger Trade Technology Pte. Ltd.

Inhibrx Biosciences

96.99
-0.9400-0.96%
Post-market: 96.990.00000.00%19:30 EDT
Volume:201.45K
Turnover:19.64M
Market Cap:1.42B
PE:-10.93
High:100.13
Open:99.30
Low:96.07
Close:97.93
52wk High:155.29
52wk Low:28.16
Shares:14.67M
Float Shares:8.64M
Volume Ratio:0.84
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.8768
EPS(LYR):-9.0434
ROE:-1773.60%
ROA:-43.61%
PB:-26.86
PE(LYR):-10.72

Loading ...

Inhibrx Q1 Operating Income USD -30.927 Million

THOMSON REUTERS
·
May 15

Should Positive INBRX-106 Phase 2 Combo Data in Head and Neck Cancer Require Action From Inhibrx Biosciences (INBX) Investors?

Simply Wall St.
·
May 12

Inhibrx Biosciences Reports Positive Interim Phase 2 Results

TIPRANKS
·
May 12

Inhibrx’s INBRX-106 shows potential benefit in HNSCC

TIPRANKS
·
May 12

Inhibrx says INBRX-106 plus pembrolizumab lifts Phase 2 HNSCC response rate to 44%

Reuters
·
May 11

Inhibrx Reports Interim Phase 2 Data for Inbrx-106 in First-Line Hnscc; Initial Results Demonstrate Potential Costimulatory Benefit Over Pd-1 Monotherapy

THOMSON REUTERS
·
May 11

Inhibrx Biosciences Inc - up to 15-Fold Increase in Systemic T-Cell Expansion With Inbrx-106 Plus Pembrolizumab

THOMSON REUTERS
·
May 11

Inhibrx Biosciences Inc - Three Complete Radiographic Responses Observed With Inbrx-106 Plus Pembrolizumab

THOMSON REUTERS
·
May 11

Inhibrx Biosciences Inc - Inbrx-106 Plus Pembrolizumab Achieves 44.0% Confirmed Orr VS 21.4% With Pembrolizumab Alone

THOMSON REUTERS
·
May 11

Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences

Dow Jones
·
May 09

Inhibrx Biosciences' Shares Up Ahead of Phase 2 Head and Neck Cancer Drug Data

Dow Jones
·
May 09

Inhibrx to webcast interim Phase 2 HexAgon results for INBRX-106 in HNSCC

Reuters
·
May 09

BRIEF-Inhibrx to host webcast presentation to provide clinical update on INBRX-106 HexAgon study in first line HNSCC

Reuters
·
May 09

Inhibrx to Host Webcast Presentation to Provide Clinical Update on Inbrx-106 Hexagon Study in First Line Hnscc

THOMSON REUTERS
·
May 09

A Look At Inhibrx Biosciences (INBX) Valuation After New Ozekibart Data And BLA Submission

Simply Wall St.
·
May 02

Inhibrx initiated with an Outperform at LifeSci Capital

TIPRANKS
·
Apr 24

Why Inhibrx Biosciences (INBX) Is Up 44.3% After Ozekibart Colorectal Cancer Efficacy Update And What's Next

Simply Wall St.
·
Apr 24

Inhibrx Biosciences announces annual shareholder meeting webcast

Reuters
·
Apr 24

A Look At Inhibrx Biosciences (INBX) Valuation After Recent Ozekibart And Chondrosarcoma Trial Updates

Simply Wall St.
·
Apr 23

Small U.S. Stocks Rise; Inhibrx Biosciences Climbs Highest

Dow Jones
·
Apr 23